4 news items
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
MREO
14 Jun 24
. About Mereo BioPharma Mereo BioPharma is a biopharmaceutical company focused on the development of innovative
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
MREO
RARE
11 Jun 24
. About Mereo BioPharma Mereo BioPharma is a biopharmaceutical company focused on the development of innovative
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
MREO
3 Apr 24
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has two rare
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
MREO
27 Mar 24
on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates, setrusumab for the treatment
- Prev
- 1
- Next